LONG-ACTING TECHNOLOGY FOR MALARIA VECTOR CONTROL
In September 2022, MedinCell and the Medicines Patent Pool (MPP) MedinCell signed a licence agreement for a candidate long-acting drug formulation that could be used to fight malaria in low- and middle-income countries.
This non-exclusive licence agreement, made possible with funding to both parties from global health agency Unitaid, will enable MPP to support the identification of suitable partners for the development and commercialisation of mdc-STM, an injectable formulation of ivermectin with a three-month action-duration, using MedinCell’s BEPO® technology. Under the terms of the licence, the manufacturing can be carried out in any country worldwide, for distribution in low- and middle-income countries.
|Field||Administration to impact on malaria transmission|
|Eligibility for sublicences||Sublicences can be issued to any qualified entity in any country of the world (for development and/or commercialisation)|
|Manufacturing||Allows manufacturing worldwide|
|Geographical scope for sale||Allows for sale in all LMICs. The licence contains a requirement of Affordable Price|
|Sales outside the licensed territory||Allowed if country issues compulsory license, or where the activity does not infringe a licensed patent granted and in force or rely upon licensed know-how|
|Royalties||Sublicences are royalty-free for sales in public market in LMICSs. Reasonable royalties (to be agreed before the Commercialisation Agreement signature) are due for the sales in private market in LMICs.|
|Quality assurance||Products will comply with the following standards: WHO Pre-qualification Programme(PQ), Global Fund/Unitaid Expert Review Panel(ERP), US FDA and/or another WHO Listed Regulatory Authority as agreed between MPP & sublicensee|
|Data exclusivity||MPP sublicensee will not seek and will waive, regulatory exclusivity in LMICs in relation to any data relating to licensed products.|
|Patent disclosure||Obligation for licensor to list licensed patents, also for improvements of LA. A right to maintain and enforce them remains with licensor|
|Term||Until last licensed patent has expired, lapsed or has been invalidated|
|Grant back||Parties will discuss: